Epirubicine

DRUG3 trials

Sponsors

GBG Forschungs GmbH, Hoffmann-La Roche, Centre Jean Perrin

Conditions

Breast CancerPathological Response Rate

Phase 2

A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer

CompletedNCT00773695

Hoffmann-La RocheBreast Cancer

Start: 2008-11-07End: 2022-11-09Updated: 2023-01-09

Assessment of the Efficacy of the Neoadjuvant Combination: Chemotherapy-Targeted Therapy in Breast Cancer.

CompletedNCT00933517

Centre Jean PerrinPathological Response Rate

Start: 2009-09-30End: 2011-10-31Updated: 2014-03-21

Phase 3

A Study to Compare ETC vs. EC-TX and Ibandronate vs. Observation in Patients With Node-positive Primary Breast Cancer (GAIN)

CompletedNCT00196872

GBG Forschungs GmbHBreast Cancer

Start: 2004-07-31End: 2014-06-30Target: 3000Updated: 2014-07-17

Related Papers

Molecular profiling of chemotherapy-resistant breast cancer reveals DNA methylation remodeling associated with the acquisition of paclitaxel resistance.

2026-01-02

High mid-treatment tumour RNA disruption in patients with HER2-negative breast cancer is associated with improved disease-free survival after neoadjuvant chemotherapy

Breast Cancer Research2025-08-111 citations

Abstract 5627: Spatial protein profiling by cyclic immunofluorescence to interpret and improve bulk tumor-based predictor of response to chemotherapy with bevacizumab in neoadjuvant breast cancer treatment

Cancer Research2023-04-04

TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer.

2021-08-141 citations

Relevance of tumour-infiltrating lymphocytes, PD-1 and PD-L1 in patients with high-risk, nodal-metastasised breast cancer of the German Adjuvant Intergroup Node-positive study.

2019-05-0740 citations

Time series analysis of neoadjuvant chemotherapy and bevacizumab-treated breast carcinomas reveals a systemic shift in genomic aberrations.

2018-11-2920 citations

Molecular characteristics in breast cancer tumors treated with neoadjuvant chemotherapy with and without bevacizumab: Results from NeoAva— Randomized phase II study.

Journal of Clinical Oncology2015-05-201 citations

Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact.

2014-05-1492 citations